Samsung Biologics Reports 64% Jump in FY19 Earnings, Sees Global Expansion in 2020

  • Published Month : Tuesday, 04 Feb 2020 12:00 pm

Debt to Equity improved with base effects from stock disposal gains with the exercise of Biogen call option in 2018.  Cash flow from operating activities also turned profitable due to growth in augmented sales and operating performance. A significant growth was seen in the number of Contract Development (CDO) contracts signed in 2019, and the total number of Contract Manufacturing (CMO) contracts signed increased by 30%.

Samsung Biologics, a pharmaceutical Contract Manufacturing Organization (CMO), recorded high for the fiscal year 2019, reporting 30.9% growth in sales at 701.6 billion won, and 64.6% growth in operating profit at 91.7 billion won compared to the previous year. The strong performance was driven by increased operations at all three manufacturing plants.  

Debt to Equity improved with base effects from stock disposal gains with the exercise of Biogen call option in 2018.  Cash flow from operating activities also turned profitable due to growth in augmented sales and operating performance. A significant growth was seen in the number of Contract Development (CDO) contracts signed in 2019, and the total number of Contract Manufacturing (CMO) contracts signed increased by 30%.

Since its launch in 2011, Samsung Biologics has been expanding its service offerings beyond CMO with state-of-the-art development, manufacturing, and laboratory testing services. The company has continued positive momentum and recently further reinforced its manufacturing capabilities in small scale manufacturing and aseptic filling.

"With a flawless regulatory approval record, the highest capacity, and the fastest throughput, Samsung Biologics continues to demonstrate strong growth as a world-class CMO. With our background in business excellence and our unwavering commitment to quality and healthcare, we are uniquely positioned to support the evolving needs in the development, manufacturing, and testing of biological products to the benefit of our clients, patients, and shareholders," Dr. Tae Han Kim, CEO of the company added.

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

A PHP Error was encountered

Severity: Warning

Message: count(): Parameter must be an array or an object that implements Countable

Filename: amp/news_details_amp.php

Line Number: 252

Backtrace:

File: /home/smartmarketnews/public_html/application/views/amp/news_details_amp.php
Line: 252
Function: _error_handler

File: /home/smartmarketnews/public_html/application/controllers/Amp_controller.php
Line: 41
Function: view

File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Visit Our Sites
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy